Christer Sundström
#155,427
Most Influential Person Now
Researcher
Christer Sundström's AcademicInfluence.com Rankings
Christer Sundströmbiology Degrees
Biology
#11940
World Rank
#15380
Historical Rank
Molecular Biology
#1891
World Rank
#1920
Historical Rank
Biochemistry
#2006
World Rank
#2147
Historical Rank
Download Badge
Biology
Christer Sundström's Degrees
- Masters Biochemistry University of Gothenburg
- Bachelors Chemistry Uppsala University
Why Is Christer Sundström Influential?
(Suggest an Edit or Addition)Christer Sundström's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) (1976) (2399)
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. (2006) (820)
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. (2008) (592)
- Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. (2012) (464)
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (2005) (421)
- Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. (2006) (404)
- Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. (2002) (381)
- Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. (2003) (350)
- Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. (2004) (295)
- Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. (1974) (293)
- Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1 (1994) (277)
- Ultraviolet radiation exposure and risk of malignant lymphomas. (2005) (265)
- Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur (2012) (247)
- Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells (1980) (245)
- Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis (2005) (220)
- Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma (2002) (197)
- Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. (2003) (188)
- Predicting malignancy grade with PET in non-Hodgkin's lymphoma. (1995) (177)
- The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). (2010) (174)
- Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. (2007) (170)
- CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. (2001) (165)
- Formation and growth of multicellular spheroids of human origin (1983) (164)
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. (2016) (160)
- 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau (2016) (155)
- Establishment and characteristics of two unique cell lines from patients with lymphosarcoma (1974) (152)
- Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. (1992) (144)
- Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. (2004) (137)
- Expression of CCL5/RANTES by Hodgkin and Reed‐Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue (2003) (133)
- Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma (2009) (131)
- Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. (2000) (131)
- Mast cells express functional CD30 ligand and are the predominant CD30L‐positive cells in Hodgkin's disease (2001) (128)
- Clinical significance of the WHO grades of follicular lymphoma in a population‐based cohort of 505 patients with long follow‐up times (2012) (124)
- Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. (2003) (119)
- SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study (2014) (118)
- Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. (1983) (110)
- 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments (2013) (108)
- Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. (2013) (106)
- Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia (2002) (105)
- Somatic hypermutation and VH gene usage in mantle cell lymphoma (2002) (99)
- Functional and morphological characterization of cultures of Kupffer cells and liver endothelial cells prepared by means of density separation in Percoll, and selective substrate adherence (2004) (96)
- A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study (2007) (95)
- Impact of TP53 mutation and 17p deletion in mantle cell lymphoma (2011) (93)
- Immune functions of human synovial cells. Phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. (1982) (93)
- Detection of tumor‐specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients (1994) (89)
- Hepatitis C infection and risk of malignant lymphoma (2008) (83)
- A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival (2014) (81)
- Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. (1989) (80)
- Mast cell infiltration is a favourable prognostic factor in diffuse large B‐cell lymphoma (2007) (79)
- DNA repair genes are selectively mutated in diffuse large B cell lymphomas (2013) (78)
- Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. (2006) (77)
- Surface receptors on human haematopoietic cell lines. (1976) (73)
- Chromosomal Imbalances in Diffuse Large B-Cell Lymphoma Detected by Comparative Genomic Hybridization (2002) (72)
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. (2016) (71)
- Original article: Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study (1991) (69)
- Atopy and risk of non-Hodgkin lymphoma. (2007) (69)
- Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma (2003) (68)
- Surface characteristics of the U-937 human histiocytic lymphoma cell line: specific changes during inducible morphologic and functional differentiation in vitro. (1981) (67)
- Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. (1999) (66)
- Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. (1992) (63)
- Use of cellular or cordless telephones and the risk for non-Hodgkin’s lymphoma (2005) (62)
- Monocytic origin of the human hematopoietic cell line U‐937 and its convertibility to macrophages evidenced by isoenzyme mapping (1983) (62)
- Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications (2003) (62)
- Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group (2008) (61)
- Myeloperoxidase in human lung lavage (1990) (60)
- Nutrient intake and risk of non-Hodgkin's lymphoma. (2006) (60)
- Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B‐type chronic lymphocytic leukemia cells depending on the costimulatory activation and progression signals (1989) (60)
- Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi‐centre study comparing real‐time polymerase chain reaction and multicolour flow cytometry (2011) (56)
- Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. (2017) (55)
- Prognostic significance of flow cytometry studies in B‐cell non‐hodgkin lymphoma (1990) (54)
- Analysis of a Clonally Related Mantle Cell and Hodgkin Lymphoma Indicates Epstein-Barr Virus Infection of a Hodgkin/Reed-Sternberg Cell Precursor in a Germinal Center (2003) (53)
- Telomerase activity in Hodgkin's disease. (1998) (52)
- Association between histamine-containing mast cells and sensory nerves in the skin and airways of control and capsaicin-treated pigs (1991) (52)
- A Novel B-cell Line (U-2932) Established from a Patient with Diffuse Large B-cell Lymphoma Following Hodgkin Lymphoma (2002) (52)
- Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis (2012) (48)
- miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. (2015) (48)
- Recovering DNA and Optimizing PCR Conditions from Microdissected Formalin-Fixed and Paraffin-Embedded Materials (2001) (48)
- Enrichment of epidermal Langerhans cells: studies with a monolayer technique and flow cytometry sorting. (1982) (47)
- T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab (2011) (47)
- TET2 mutations in B cells of patients affected by angioimmunoblastic T‐cell lymphoma (2017) (46)
- Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. (2005) (46)
- Medication use and risk of non-Hodgkin's lymphoma. (2005) (45)
- [18F] FDG PET in gastric non-Hodgkin's lymphoma. (1997) (45)
- Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade (2014) (45)
- Both CD4+ FoxP3+ and CD4+ FoxP3− T cells from patients with B‐cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro (2011) (44)
- Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. (2005) (44)
- Cytochemical Profile of Human Haematopoietic Biopsy Cells and Derived Cell Lines (1977) (43)
- U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden (2017) (43)
- Angiogenesis and mast cells in Hodgkin lymphoma (2005) (43)
- Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor‐B acute lymphoblastic leukemia (1999) (42)
- In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). (1993) (40)
- Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. (1991) (39)
- Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed‐Sternberg cells of patients with Hodgkin's disease (1997) (37)
- The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia (2006) (36)
- Lymphoma incidence in a Swedish county during 1969-1987. (1992) (36)
- Elevated serum levels of soluble vascular cell adhesion molecule‐1 (sVCAM‐1) closely reflect tumour burden in chronic B‐lymphocytic leukaemia (1998) (36)
- Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. (2009) (36)
- Characterization of a Human Basophil‐Like Cell Line (LAMA‐84) (1996) (35)
- The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. (1995) (35)
- PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS (2021) (34)
- Serum thymidine kinase as a prognostic marker in Hodgkin's disease. (1985) (34)
- Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. (1998) (33)
- Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro (2007) (33)
- Soluble vascular cell adhesion molecule‐1 (sVCAM‐1) is an independent prognostic marker in Hodgkin's disease (1998) (33)
- Dose-Dense Induction Followed by Autologous Stem Cell Transplant (ASCT) as 1st Line Treatment in Peripheral T-Cell Lymphomas (PTCL) - A Phase II Study of the Nordic Lymphoma Group (NLG). (2006) (33)
- Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells (2009) (32)
- Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease (2015) (32)
- Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma (2007) (31)
- Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. (2005) (31)
- IL‐9 expression contributes to the cellular composition in Hodgkin lymphoma (2006) (31)
- Immunophenotype of hairy‐cell leukemia (1990) (31)
- Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic lymphocytic leukemia cells to simultaneous immunoglobulin secretion and DNA synthesis. (1988) (31)
- Early lesions in lymphoid neoplasia (2012) (30)
- Surface antigen expression and correlation with variable heavy‐chain gene mutation status in chronic lymphocytic leukemia (2003) (30)
- In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay. (1994) (29)
- Donor or Recipient Origin of Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation (2014) (29)
- Alterations of the CD58 gene in classical Hodgkin lymphoma (2015) (29)
- Myeloperoxidase in human lung lavage (1990) (29)
- Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation (2018) (28)
- Presence of alpha-naphthyl acetate esterase activity in human haematopoietic cell lines and in fresh biopsy specimens of lymphoma and myeloma. (2009) (28)
- Patients suffering from both Hodgkin's disease and non‐Hodgkin's lymphoma: A clinico‐pathological and immuno‐histochemical population‐based study of 32 patients (1997) (28)
- A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. (1997) (27)
- Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. (2011) (27)
- Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. (1996) (27)
- Population-based experience on primary central nervous system lymphoma 2000–2012: the incidence is increasing (2017) (26)
- Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas (2015) (26)
- hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. (2011) (25)
- Morphologic classification of non-Hodgkin's lymphoma. I. Retrospective analysis using the Kiel classification. (1982) (25)
- Expression of the human germinal‐centre‐associated lymphoma protein in diffuse large B‐cell lymphomas in patients with rheumatoid arthritis (2008) (24)
- Similar Humoral Immunity Parameters in Chronic Lymphocytic Leukemia Patients Independent of VH Gene Mutation Status (2004) (23)
- Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. (2002) (23)
- Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome (2009) (23)
- Mitoxantrone, etoposide and ara‐C vs doxorubicin‐DNA, ara‐C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison (1995) (23)
- A study of the reproducibility of the diagnostic criteria for acute leukaemia. (2009) (22)
- A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia. (1991) (22)
- A comparative study of proliferation‐associated parameters in b‐cell non‐hodgkin lymphoma (2006) (21)
- The Serum Levels of Eosinophil Cationic Protein (ECP) Are Related to the Infiltration of Eosinophils in the Tumours of Patients with Hodgkin's Disease (2001) (21)
- Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14) (2006) (20)
- Establishment and characterization of a human EBV-negative B cell line (MN 60). (1982) (20)
- More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia (2003) (20)
- p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma (2020) (20)
- Alternative myelomonocytic differentiation of HL-60 reflects dual prospective potency of promyelocytes in human. (1984) (20)
- Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma (2020) (20)
- Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia (2005) (18)
- Lysis of human B‐lymphocyte‐derived lymphoma/leukemia cells of established cell lines by interferon‐activated natural killer (NK) cells (1981) (18)
- Prognostic factors in non-Hodgkin lymphoma stage I treated with radiotherapy. (1989) (18)
- Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant (2018) (18)
- Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. (2021) (17)
- Micro-PIXE analysis of macro- and trace elements in blood cells and tumors of patients with breast cancer (1987) (17)
- Morphological classification of non-Hodgkin malignant lymphoma. II. Comparison between Rappaport's classification and the Kiel classification. (2009) (17)
- Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. (1995) (16)
- Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis. (1995) (16)
- U‐2940, a human B‐cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma (2006) (16)
- Telomere length and correlation with histopathogenesis in B‐cell leukemias/lymphomas (2007) (15)
- Association between HLA-A1 and -A2 types and Epstein–Barr virus status of post-transplant lymphoproliferative disorder (2016) (15)
- Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy (2020) (14)
- Characterization of A U‐937 subline which can be induced to differentiate in serum‐free medium (1992) (14)
- In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia (1992) (14)
- Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma (1999) (14)
- Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy (2014) (14)
- Comparative Analysis of Detection Systems for Evaluation of PCR Amplified Immunoglobulin Heavy‐Chain Gene Rearrangements (1997) (13)
- Low cytidine deaminase levels in human hematopoietic cell lines. (1987) (13)
- Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia. (2009) (13)
- (90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3) (2009) (13)
- Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance. (1998) (13)
- In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. (2009) (13)
- Rituximab as a Single Agent and in Combination With Interferon Alfa-2a as Treatment of Untreated and First-Relapse Follicular or Other Low-Grade Lymphomas: A Randomized Phase II Study (M 39035) (2001) (13)
- VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia (2004) (13)
- Bimodal differentiation prospectives for promyelocytes. (1985) (12)
- Diagnostic and prognostic significance of serum measurements of lactoferrin, lysozyme and myeloperoxidase in acute myeloid leukemia (AML): Recognition of a new variant, high‐lactoferrin AML (1987) (12)
- The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues (2014) (12)
- Phenotypic and cytogenetic characteristics of a new epstein‐barr virus negative cell line (SKW 4) derived from A B‐Cell lymphoma (2007) (12)
- Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. (2020) (12)
- Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren’s syndrome (2018) (12)
- Population-based study of patients with primary Sjögren’s syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences (2020) (12)
- The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin‐3 or granulocyte‐macrophage colony stimulating factor (1999) (12)
- Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. (2003) (11)
- High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01) (2011) (11)
- Differential expression of cysteinyl leukotriene receptor 1 and 15-lipoxygenase-1 in non-Hodgkin lymphomas. (2008) (11)
- Radiation therapy of non-Hodgkin's lymphoma stages I and II. (1982) (11)
- Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01) (2010) (10)
- Surface glycoprotein patterns of B type chronic lymphocytic leukaemia cells correlate with the clinical activity of the disease. (2009) (10)
- In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low‐grade non‐Hodgkin's lymphoma (2002) (10)
- Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population‐based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002–2006 (2010) (10)
- Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes (2015) (9)
- In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia (2005) (9)
- Nonradioactive detection of monoclonal immunoglobulin heavy chain gene rearrangement with PCR-SSCP. (1995) (9)
- Relapsed Hodgkin's Lymphoma: Immunostaining Patterns in Relation to Survival (2002) (9)
- Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study. (2007) (9)
- The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis (2017) (9)
- Serum levels of soluble vascular cell adhesion molecule‐1 (sVCAM‐1) are elevated in advanced stages of non‐Hodgkin's lymphomas (1998) (9)
- Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin (2012) (8)
- Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01) (2010) (7)
- Identification of uniquely expressed transcription factors in highly purified B‐cell lymphoma samples (2010) (7)
- IGHV3‐21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia (2010) (7)
- Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low‐grade lymphoproliferative disorders using the FMCA (1999) (7)
- Multiclonality and altered RFLP patterns for immunoglobulin heavy-chain and T-cell receptor genes in relapsing lymphomas. (1994) (7)
- Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression (2021) (7)
- In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia – rolipram and prednisolone active in cells from patients with poor prognosis (2009) (7)
- Aggressive treatment improves survival in adult acute lymphoblastic leukemia (1988) (7)
- In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia. (2011) (7)
- Sporadic occurrence of non-diagnosed IgG4-related disease in lymphoma patients with a previous Sjögren’s syndrome diagnosis (2016) (7)
- Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study (2010) (7)
- A novel human B‐cell line (U‐2904) bearing t(8;14) and t(14;18) translocations (1995) (7)
- Expression of possible targets for new proteasome inhibitors in diffuse large B‐cell lymphoma (2017) (7)
- Effect of alpha-IFN on cytokine-induced antigen expression and secretion of TNF, LT and IgM in HCL. (1991) (6)
- The BCL-2 promoter (−938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia (2008) (6)
- Genome-wide microarray-based comparative genomic hybridization analysis of lymphoplasmacytic lymphomas reveals heterogeneous aberrations (2009) (6)
- Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells (2005) (5)
- CD30 expression and survival in posttransplant lymphoproliferative disorders (2020) (5)
- U‐2973, a novel B‐cell line established from a patient with a mature B‐cell leukemia displaying concurrent t(14;18) and MYC translocation to a non‐IG gene partner (2008) (5)
- Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas. (1998) (5)
- Immunophenotype analysis of B‐CLL lymphoma and immunocytoma (1989) (5)
- Isozymes of acid esterase and acid phosphatase in permanent human hematopoietic cell lines. (1982) (5)
- High-dose therapy and autologous stem cell transplant as 1. line treatment in peripheral T-cell lymphomas (2005) (4)
- Effect of α-IFN on cytokine-induced antigen expression and secretion of TNF, LT and IgM in HCL (1991) (4)
- V(a)3-21 gene utilizing chronic lymphocytic leukemias display restricted V lambda 2-14 gene usage and homologous CDR3s. (2002) (4)
- PD-L1 and IDO1 are important immunosuppressive molecules in primary diffuse large B-cell lymphoma of the CNS (2020) (4)
- Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome (2015) (4)
- Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study (2015) (4)
- Biology of human malignant lymphomas in vitro : characterization of biopsy cells and established cell lines (1977) (4)
- Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia. (2012) (4)
- Serum Levels of Soluble CD 30 and Their Relationship to Tumour Burden and Prognosis in Patients with Hodgkin's Disease. (1997) (3)
- [Limit investigation in cancer of unknown primary site]. (2005) (3)
- AN ESTABLISHED HUMAN CELL LINE DERIVED FROM A MALIGNANT MEDIASTINAL TERATOMA (1980) (3)
- Mouse red cell receptors on human hematopoietic cell lines. (1980) (3)
- LEUKEMIA AND LYMPHOMA (1974) (3)
- Polymerase Chain Reaction‐Single‐Strand Conformational Polymorphism Analysis of Antigen Receptor Rearrangements in Monitoring Therapeutic Effect in Childhood ALL (1998) (3)
- Application of methylumbelliferylphosphate as phosphatase substrate in isoenzyme mapping. (1982) (3)
- Molecular pathology in the diagnosis of hematologic neoplasia (1997) (3)
- Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis (2019) (2)
- [Core needle biopsies for lymphoma diagnosis seriously affect diagnostics, treatment development and research]. (2017) (2)
- Assessment of Drug Activity and Proliferation Ex Vivo for Prediction of Outcome in Aggressive Non-Hodgkin's Lymphomas (2002) (2)
- Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group (2012) (2)
- EBV-positivity in Hodgkin´s disease in an unselected population (1998) (2)
- Patients above Sixty Years Lymphoma Treated with a New Strategy of Age with Hodgkin's (2002) (2)
- MYC+ Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report (2011) (2)
- Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity (2022) (2)
- VH gene mutation analysis distinguishes a subgroup of chronic lymphocytic leukemia with low-mutated VH genes and inferior outcome. (2004) (2)
- Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time (2011) (2)
- prognosis in chronic lymphocytic leukemia CD38 expression is a poor predictor for VH gene mutational status and (2013) (1)
- Serum levels of soluble vascular cell adhesion molecule‐1 (sVCAM‐1) are elevated in advanced stages of non‐Hodgkin's lymphomas (1999) (1)
- Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial (2022) (1)
- Risk of EBV-Positive Hodgkin Lymphoma Varies Over 30-Fold by HLA Class I Genotype and History of Infectious Mononucleosis. (2009) (1)
- Nordic MCL2-3 Trials : Mirna-18B Overexpression Identifies a Mantle Cell Lymphoma Subgroup with Poor Survival and Improves Mipi-B Prediction of Prognosis (2014) (1)
- The human follicular dendritic cell line FDC-1 binds immune complexes and promotes somatic hypermutation. (2001) (1)
- FRI0166 Does biological therapy alter the lymphoma risk or distribution of lymphoma subtypes in patients with ra? (2013) (1)
- Invitro testing ofchemotherapeutic drugcombinations inacute myelocytic leukaemia using thefluorometric microculture cytotoxicity (1993) (1)
- A Follicular Dendritic Cell Line Promotes Somatic Hypermutations in Ramos cells In Vitro (2009) (1)
- [Updating of the Kiel classification of malignant non-Hodgkin lymphomas]. (1989) (1)
- Acute lymphoblastic leukaemia in adults in Sweden 1977-84: a retrospective analysis. Swedish ALL-Group. (1989) (1)
- Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies. (2021) (1)
- High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis (2012) (1)
- Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children (2022) (1)
- alpha-Interferon inhibits spontaneous and induced DNA synthesis in hairy cell leukemia. (1992) (1)
- Loss of function mutations of BCOR in classical Hodgkin lymphoma (2021) (1)
- IgE‐producing low‐grade non‐Hodgkin lymphoma (1988) (1)
- Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival. (2005) (1)
- OP0108 Aggressive lymphomas (diffuse large b cell lymphomas) are overrepresented in ra patients (2001) (0)
- A5.27 Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma (2013) (0)
- B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma. (2023) (0)
- mantle cell lymphoma Mutated VH genes and preferential VH3-21 use define new subsets of (2013) (0)
- Ultrastructure of Cultured Leukemia Cell Lines (1984) (0)
- In mantle cell lymphoma (MCL) the MCL-International Prognostic Index (MIPI) is a better predictor of event-free and overall survival than International Prognostic Index (IPI) in patients receiving intensive 1st line treatment including ASCT (2009) (0)
- Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases (2023) (0)
- lymphocytic leukemia indicate a role for antigen selection in the development of chronic Subsets with restricted immunoglobulin gene rearrangement features (2013) (0)
- Rheumatoid Arthritis and Risks of Malignant Lymphoma : Are Risks Still Increased? (2012) (0)
- Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group 1998–2006 (2008) (0)
- CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years (2008) (0)
- Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders (2021) (0)
- How Many Ontogenetic Roads to Mantle-Cell Lymphoma? : Immunogenetic and Immunohistochemical Evidence (2014) (0)
- Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs : Long-Term Follow-up of Risks and Lymphoma Subtypes (2015) (0)
- Lymphomas in RA patients treated with TNF-blockers. Cases found in a post-marketing surveillance in Sweden (2004) (0)
- Arachidonic Acid Metabolism-Related Molecules as Candidate Markers in Subclassification of Lymphoma (2008) (0)
- LYMPHOID NEOPLASIA miR-18 b overexpression identi fi es mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator (2015) (0)
- Telomere length in mature B cell malignancies - correlation with cellular origin with respect to the germinal center (2005) (0)
- Identification of Polymorphisms in the ECP - gene. Relation to disease activity in Hodgkin Lymphoma (2002) (0)
- The Journal of Rheumatology Subtypes, Clinical Characteristics, and Outcome Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: (2015) (0)
- leukemia with special reference to VH gene mutation status Telomere length as a prognostic parameter in chronic lymphocytic (2013) (0)
- Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials (2014) (0)
- Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab (2011) (0)
- Minimal residual disease assessment in childhood acute lymphoblastic leukemia : Results of a Swedish multi-centre study comparing real-time PCR and multi-colour flow cytometry (2009) (0)
- Expression of CCL5/RANTES in Hodgkin lymphoma, a possible explanation for mast cell infiltration (2003) (0)
- 18FDG PET in gastric non-Hodgkin´s lymphoma. Scan Eur Congr Radiol, Vienna. (1997) (0)
- Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment (2022) (0)
- Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort (2013) (0)
- The role of Moraxella in the pathogenesis of IgD(+) nodular lymphocyte predominant Hodgkin lymphoma (2017) (0)
- Identification and gene expression analysis of the side population subclone in mantle cell lymphoma (2017) (0)
- 90y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem Cell Support as Therapy for Advanced Mantle Cell Lymphoma. - Preliminary Results From the Third Nordic II Study (MCL3) (2009) (0)
- HpaII Polymerase Chain Reaction Restriction Fragment Length Polymorphism in the Human CD19 Gene on 16p11 (1998) (0)
- SAT0309 Primary Sjögren's Syndrome and Lymphoma – A Population-Based Study Focused on Lymphoma as Exclusion Criterion for Primary Sjögren's Syndrome Diagnosis (2016) (0)
- Telomere length and VH gene mutation status in chronic lymphocytic leukemia: Differences related to gender, age and sample site (2003) (0)
- Analysis of IG/TCR gene rearrangements in Swedish childhood acute lymphoblastic leukemia diagnosed 2002-2006: a multi-centre study supporting the applicability of real-time-PCR for minimal residual disease assessment (2009) (0)
- Malignant Lymphoma In Granulomatosis With Polyangiitis (2017) (0)
- Diffuse large B-cell lymphomas in rheumatoid arthritis display a predominance of non-germinal center type (2005) (0)
- Paper 81946 abstract 160359 0 (2015) (0)
- SAT0232 Lymphoma in patients with primary sjögren’s syndrome: A population-based study of lymphoma subtypes, risk factors and survival (2013) (0)
- Ro52/TRIM21 Expression is Decreased in Malignant B Cells (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christer Sundström?
Christer Sundström is affiliated with the following schools:
